We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01677962
Recruitment Status : Completed
First Posted : September 3, 2012
Last Update Posted : December 15, 2016
Information provided by (Responsible Party):
Carolyn Britten, Medical University of South Carolina

Brief Summary:
The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for this disease. Dendritic cells are cells that are present in the body's immune system that help your body fight disease.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Non-resectable Biological: Poly-ICLC Biological: dendritic cell Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility and Safety Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Study Start Date : August 2012
Actual Primary Completion Date : September 2014
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arm Intervention/treatment
Experimental: dendritic cell and Poly-ICLC vaccination
Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
Biological: Poly-ICLC
Biological: dendritic cell

Primary Outcome Measures :
  1. Primary Outcome [ Time Frame: from study consent to last treatment (Day 56) ]

    Number of Participants With Adverse Events (AEs)

    Evaluate the frequency of toxicities by type and severity, and dose of study drug according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.

  2. Primary Objective [ Time Frame: from study consent to last treatment (Day 56) ]
    Determining the feasibility of generating dendritic cells and administering these cells as a vaccine to patients

Secondary Outcome Measures :
  1. Secondary Outcome [ Time Frame: Average three months Per Participant ]
    Number of Participants With Tumor Response

  2. Secondary Objective [ Time Frame: Post treatment ]
    Measure overall Survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Each of the following criteria must be met in order for a patient to be considered eligible for enrollment.

  • Patients must have histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma that is locally advanced and unresectable. Patients with endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible.
  • Patients must have measurable disease per RECIST 1.1. One or more tumors measurable on CT scan per RECIST 1.1. (Eisenhauer)
  • Patients may have had prior cancer therapy. Patients do not need to demonstrate progression to be considered for this trial.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  • Age ≥ 18 years.
  • Patient must have an expected life expectancy greater than 3 months.
  • Signed, written IRB-approved informed consent.
  • Bilirubin ≤ 3 times upper limit of normal (CTCAE Grade 2 baseline)
  • AST (SGOT), ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)
  • Serum creatinine ≤1.5 XULN (CTCAE Grade 1 baseline)
  • Acceptable hematologic status, defined as:
  • Absolute neutrophil count ≥ 1000 cells/mm3
  • Platelet count ≥ 75,000 (plt/mm3), (CTCAE Grade 1 baseline)
  • Hemoglobin ≥ 9 g/dL.
  • Urinalysis with no clinically significant abnormalities.
  • PT and PTT ≤ 1.5 X ULN after correction of nutritional deficiencies that may contribute to prolonged PT/PTT

Exclusion Criteria:

Each of the following criteria should not be present in order for the patient to be considered eligible for enrollment.

  • Patients must not have metastatic disease. Patients with evidence of metastatic disease at the time of screening or prior to the administration of DC vaccination will be considered a screen failure and excluded from study.
  • Prior surgery is allowed provided at least 14 days has elapsed between surgery and registration. Prior radiation/chemo is allowed provided that at least 28 days have elapsed since the last treatment.
  • Patients must not have any serious uncontrolled acute or chronic medical condition that would interfere with this treatment. Examples would include active acute or chronic infection requiring antibiotics, uncontrolled cardiovascular, endocrine, or infectious disease.
  • Patient must not have clinically significant ascites.
  • Patients must not have significant ongoing cardiac problems, myocardial infarction within the last six months, uncontrolled hypertension, unstable angina, uncontrolled arrhythmia or congestive heart failure.
  • Patients with known brain metastases are not eligible. However, brain-imaging studies are not required for eligibility if the patient has no neurologic signs or symptoms. If brainimaging studies are performed, they must be negative for disease. Patients must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol treatment.
  • Due to the undetermined effect of this treatment regimen in patients with HIV-1 infection and the potential for serious interaction with anti-HIV medications, patients known to be infected with HIV are not eligible for this study.
  • Due to the possibility of harm to a fetus or nursing infant from this treatment regimen, patients must not be pregnant or nursing. Women of child bearing potential must have a negative pregnancy test completed during study screening. Women and men of reproductive potential must have agreed to use an effective contraceptive method.
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01677962

Layout table for location information
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Layout table for additonal information
Responsible Party: Carolyn Britten, Chief, Hematology/Oncology Division, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT01677962    
Other Study ID Numbers: 101778
First Posted: September 3, 2012    Key Record Dates
Last Update Posted: December 15, 2016
Last Verified: December 2016
Keywords provided by Carolyn Britten, Medical University of South Carolina:
locally advanced, unresectable pancreatic adenocarcinoma
dendritic cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Interferon Inducers
Immunologic Factors
Physiological Effects of Drugs